Regeneron Valuation Scrutiny Follows EYLEA HD FDA Approval
Regeneron Pharmaceuticals (REGN) faces valuation scrutiny after the FDA approved extended dosing intervals for its EYLEA HD treatment. This regulatory development could impact the company's market…















